NCT07485569Not yet recruitingPhase 1
Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial
Source: EU CTIS (euclinicaltrials.eu) · Last updated 22 Jul 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 14 Mar 2026
- Start date
- 1 Jun 2026
- Lead sponsor
- Stichting Radboud University Medical Center
- Diseases
- Thyroid cancer
- NCT number
- NCT07485569
- EU CT number
- 2023-507214-28-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Radboud universitair medisch centrum Stichting Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.